

PRESS RELEASE

CARDIOCEL® TO FEATURE AT PROMINENT HEART VALVE CONFERENCES

- CardioCel® to be featured at AATS Mitral Conclave meeting in New York, NY, USA, and the AATS 2015 Annual Meeting in Seattle, WA, USA

Brisbane, Australia, April 1st, 2015

Admedus Limited (ASX: AHZ) today announced that CardioCel® will be featured in a number of presentations at the American Association for Thoracic Surgery (AATS) Mitral Conclave 2015 meeting in New York and also the 95th AATS Annual Meeting in Seattle.

Admedus' lead regenerative tissue product CardioCel® will be discussed in presentations at the AATS Mitral Conclave 2015 in New York on the 23rd and 24th of April. The Mitral Conclave focuses on the repair of the Mitral Valve.

Then on Saturday, April 25th, at the AATS Annual Meeting, Admedus will sponsor the Congenital Skills Hands-On Wet Lab for surgeons to experience using CardioCel® in 3D-printed heart models.

This will be complimented by a number of presentations from world renowned surgeons during the conference. Monday afternoon, April 27th, Admedus is hosting the Twenty First Tissue Engineering Expert Review in CT Theater 1 at the AATS.

CardioCel® is a single-ply, bio-scaffold for surgeons to use in the repair of congenital heart defects, heart valves and vascular repairs.

"Admedus continues to work with leading surgeons to illustrate and demonstrate the utility of CardioCel® in cardiovascular surgery", said Admedus CEO Mr Lee Rodne. "The product's ease of use, lack of calcification and key characteristics make it a superior tissue product in these surgical applications."

Admedus is looking forward to attending both events and discussing CardioCel® with some of the world's leading heart surgeons.

Please see attachment for further events information.

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited

Tel: +61 3 9620 5454

Media:

Haley Price

Tel: +61 (0) 423 139 163

hprice@admedus.com

Media Europe & Asia

Consilium Strategic Communications

Jessica Hodgson / Ivar Milligan

Tel: +44 (0)20 3709 5700

admedus@consilium-comms.com

About Admedus Limited

Admedus (ASX: AHZ) is a diversified, global healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group lead by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com


About CardioCel[®]

CardioCel[®] is a type of cardiovascular bio-scaffold that can be used to repair congenital heart deformities and more complex heart defects.

It is used to repair diseased paediatric and adult hearts. These repairs range from routine hole-in-the-heart operations to major vessel outflow tract repairs. The CardioCel[®] scaffold may also be used to repair heart valves. CardioCel[®] has been shown to allow tissue regeneration once implanted. Some researchers postulate that stem cells play an active role in tissue regeneration, suggesting that the product facilitates endogenous stem cells and other cells to regenerate and repair damaged tissue.

CardioCel[®] is the Admedus Group's lead regenerative tissue bio-implant used in repairing heart defects, including the repair of heart valves. It is engineered via the Admedus Group's proprietary ADAPT[®] tissue engineering process to produce a durable, collagen scaffold with handling properties preferred by surgeons that avoids calcification, while supporting native cell infiltration, growth and differentiation.

CARDIO CEL




ADAPTED COLLAGEN SCAFFOLD



What you do today
matters for their
tomorrows.

Your Tissue Solution.

CardioCel® is a single-ply bioscaffold
that remains functional, durable
and free from calcification for
all your tissue needs.



**CARDIO
CEL**



ADAPTED COLLAGEN SCAFFOLD

Please join us for the
**21st Century Tissue Engineering
Expert Review**

Monday, April 27th from 1:05 – 2:00 pm

AATS Exhibit Hall CT Theater 1

*This session is not part of the AATS Annual Meeting
accredited program.*

Stop by **booth #1105**
to experience the CardioCel® difference.


Admedus is the proud sponsor of this year's
Congenital Skills Hands-On Wet Lab,
Saturday, April 25th.

CardioCel is a registered trademark of Admedus Ltd.

ADMEDUS
INNOVATIVE HEALTH SOLUTIONS

admedus.com

CARDIO CEL



ADAPTED COLLAGEN SCAFFOLD

What you do today,
matters for her tomorrows.

A single-ply bioscaffold that remains functional, durable
and free from calcification for all your tissue needs.

Please visit **booth #1105** to experience
the CardioCel® difference.

Admedus is the proud sponsor of this year's Congenital
Skills Hands-On Wet Lab, **Saturday, April 25th**

Join us today, **Monday, April 27th**
from 1:05 – 2:00 pm
in the AATS Exhibit Hall CT Theater 1

21st Century Tissue Engineering Expert Review

Geoffrey Strange, Ph.D.
Admedus Ltd., Sydney, Australia

Domenico Mazzitelli, M.D.,
German Heart Center, Munich, Germany

Prof. Robert Klautz
Leiden University Medical Center,
Leiden, The Netherlands


T. Sloane Guy, M.D.
Temple University School of Medicine,
Philadelphia, PA USA

This session is not part of the AATS Annual
Meeting accredited program.

CardioCel is a registered trademark of Admedus Ltd.

ADMEDUS
INNOVATIVE HEALTH SOLUTIONS

admedus.com



21st Century Tissue Engineering

Expert Review

Date: Monday, April 27th

Time: 1:05 - 2:00 p.m.

Place: AATS Exhibit Hall CT Theater 1

Program Agenda & Faculty

Welcome and Introduction

Geoffrey Strange, Ph.D.
Admedus Ltd., Sydney, Australia

*An Adapted Tissue Scaffold
for Cardiovascular Repair*

Domenico Mazzitelli, M.D.
German Heart Center, Munich, Germany

*Patch Reconstruction of the Mitral Valve
Extends the Possibilities for Repair*

Prof. Robert Klautz,
Leiden University Medical Center,
Leiden, The Netherlands

*Use of CardioCel® in Robotic
Mitral Valve Repair*

T. Sloane Guy, M.D.
Temple University School of Medicine,
Philadelphia, USA

This session is not part of the AATS Annual Meeting accredited program.



admedus.com